Genesis Health sits at No. 430 in our ranking with a Brief Score of 56. Here are the GLP-1 providers we'd weigh against it — ranked on the same six-factor Brief Score, top down.
Prefer a straight head-to-head? CoreAge Rx vs Genesis Health.
One price on both molecules that does not climb as you titrate — but the headline $99 and $149 are annual-plan rates, paid in full up front.
A nationwide women's provider (Gala GLP-1, from AI Coaching Inc) whose cheap compounded-tirzepatide door only opens on a yearly subscription — with, unusually, a brand-name path on the shelf beside it.
One of the few accredited providers pairing compounded pricing with brand-name access, nationwide.
A polished, high-disclosure program with strong nationwide coverage — you pay more, but you know exactly what you're paying for.
FDA warning letter, June 2026 — issued to Eden Health International Inc. dba Eden. See the FDA's warning letter database.
A rare accredited provider that pairs brand-name access with fair mid-market compounded pricing across all 50 states.
Affordable telehealth provider offering compounded semaglutide only.
FitFlow (FitFlow Health) is a 100% online compounded telehealth platform for GLP-1 weight loss - compounded semaglutide (=Wegovy) and tirzepatide (=Mounjaro).
TrueMe is a cash-pay telehealth brand offering compounded semaglutide and tirzepatide with added B vitamins, alongside NAD+, sermorelin and glutathione.
A longevity-leaning brand with one of the lowest tracked semaglutide stickers — but a thin disclosure on the rest.
On the record
The FDA issued a warning letter to Genesis Health International Inc. dba Genesis in February 2026. Genesis Health keeps its place here and its link is unchanged — but you should know the letter exists before you start care. Read it in the FDA's warning letter database.
Rankings reflect the Dose Brief Score — our editorial judgment per the methodology. Pricing and coverage reflect public disclosures at last review and change often — confirm on each provider's site. Not medical advice; see our disclosure.